Ines Vasconcelos1, Alexandra Wiesske2, Winfried Schoenegg2. 1. Berlin Oncology Center Kurfürstendamm, Kurfürstendamm 216, 10179 Berlin, Germany. Electronic address: ines.mv@gmail.com. 2. Berlin Oncology Center Kurfürstendamm, Kurfürstendamm 216, 10179 Berlin, Germany.
Abstract
INTRODUCTION: Chemotherapy for breast cancer induces alopecia, representing a major source of patient distress. This study assesses whether a scalp-cooling device is effective in reducing chemotherapy-induced alopecia, and assesses adverse treatment effects. MATERIALS AND METHODS: A prospective observational study including women with breast cancer undergoing chemotherapy and scalp cooling using a Paxman device. The primary efficacy end points were: successful hair preservation (no hair loss; <30% hair loss not requiring a wig; or <50% hair loss not requiring a wig) at the completion of chemotherapy. Secondary end points included adverse effects such as headache, pain, nausea or dizziness. RESULTS: The study enrolled 131 participants. Mean patient age was 49.8 years; 74% received anthracycline/taxane-based chemotherapy and 26% received taxane-monotherapy based chemotherapy. Hair preservation was successful in 102 women who underwent scalp cooling (71.0%; 95% CI = 63-79%). Only adverse events related to device use were collected, representing 7% (95% CI = 3-11%) of cases. CONCLUSIONS: Scalp cooling is effective in preventing hair loss among breast cancer patients undergoing standard chemotherapy treatment, and has minimal adverse effects.
INTRODUCTION: Chemotherapy for breast cancer induces alopecia, representing a major source of patient distress. This study assesses whether a scalp-cooling device is effective in reducing chemotherapy-induced alopecia, and assesses adverse treatment effects. MATERIALS AND METHODS: A prospective observational study including women with breast cancer undergoing chemotherapy and scalp cooling using a Paxman device. The primary efficacy end points were: successful hair preservation (no hair loss; <30% hair loss not requiring a wig; or <50% hair loss not requiring a wig) at the completion of chemotherapy. Secondary end points included adverse effects such as headache, pain, nausea or dizziness. RESULTS: The study enrolled 131 participants. Mean patient age was 49.8 years; 74% received anthracycline/taxane-based chemotherapy and 26% received taxane-monotherapy based chemotherapy. Hair preservation was successful in 102 women who underwent scalp cooling (71.0%; 95% CI = 63-79%). Only adverse events related to device use were collected, representing 7% (95% CI = 3-11%) of cases. CONCLUSIONS: Scalp cooling is effective in preventing hair loss among breast cancerpatients undergoing standard chemotherapy treatment, and has minimal adverse effects.
Authors: Jade Cury-Martins; Adriana Pessoa Mendes Eris; Cristina Martinez Zugaib Abdalla; Giselle de Barros Silva; Veronica Paula Torel de Moura; Jose Antonio Sanches Journal: An Bras Dermatol Date: 2020-02-15 Impact factor: 1.896
Authors: Franz-Ferdinand Bitto; Alexander König; Thuy Phan-Brehm; Thomas Vallbracht; Julian Gregor Koch; Timo Schinköthe; Matthias Wolfgarten; Sven Mahner; Nadia Harbeck; Rachel Würstlein Journal: Breast Care (Basel) Date: 2019-07-25 Impact factor: 2.860
Authors: J Bajpai; S Kagwade; A Chandrasekharan; S Dandekar; S Kanan; Y Kembhavi; J Ghosh; S D Banavali; S Gupta Journal: Breast Date: 2019-12-12 Impact factor: 4.380